First Lassa hemorrhagic shock syndrome‐on‐Chip

Thursday, 17 December 2020

Lack of experimental human models hinders research on Lassa hemorrhagic fever, a fatal viral disease, and the development of treatment strategies. No safe drug with proven efficacy exists. The team of hDMT PI Alireza Mashaghi of the Leiden Academic Centre for Drug Research of the Leiden University, reports the first chip‐based model for Lassa hemorrhagic syndrome and a new treatment option for this disease in their article in Biotechnology and Bioengineering.

The chip features a microvessel interfacing collagen network as a simple mimic for extracellular matrix, allowing for quantitative and real‐time vascular integrity assessment. Luminal infusion of Lassa virus‐like particles led to a dramatic increase in vascular permeability in a viral load‐dependent manner.

Using this platform, the authors showed that Fibrin‐derived peptide FX06 can be used to suppress the vascular integrity loss. This simple chip‐based model proved promising in the assessment of disease severity and provides an easy‐to‐use platform for future investigation of Lassa pathogenesis and drug development in a human‐like setting.

Source: Lassa hemorrhagic shock syndrome‐on‐a‐chip

Back to the news overview